Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Febrile Neutropenia Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Febrile Neutropenia Overview | 8 | 1 |
| Febrile Neutropenia Therapeutics under Development by Companies | 9 | 2 |
| Febrile Neutropenia Pipeline Products Glance | 11 | 4 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Unknown Stage Products | 14 | 1 |
| Febrile Neutropenia Products under Development by Companies | 15 | 1 |
| Febrile Neutropenia Companies Involved in Therapeutics Development | 16 | 9 |
| Apotex Inc. | 16 | 1 |
| BeyondSpring Pharmaceuticals, Inc. | 17 | 1 |
| Biogenomics Limited | 18 | 1 |
| Coherus BioSciences, Inc. | 19 | 1 |
| Dr. Reddy's Laboratories Limited | 20 | 1 |
| Richter Gedeon Nyrt. | 21 | 1 |
| Sandoz International GmbH | 22 | 1 |
| Therapeutic Proteins International, LLC | 23 | 1 |
| USV Pvt Ltd | 24 | 1 |
| Febrile Neutropenia Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 19 |
| EC-18 Drug Profile | 34 | 1 |
| filgrastim Drug Profile | 35 | 1 |
| filgrastim Drug Profile | 36 | 1 |
| filgrastim Drug Profile | 37 | 1 |
| pegfilgrastim Drug Profile | 38 | 1 |
| pegfilgrastim Drug Profile | 39 | 1 |
| pegfilgrastim Drug Profile | 40 | 1 |
| pegfilgrastim Drug Profile | 41 | 1 |
| pegfilgrastim Drug Profile | 42 | 1 |
| pegfilgrastim Drug Profile | 43 | 2 |
| pegfilgrastim Drug Profile | 45 | 1 |
| pegfilgrastim Drug Profile | 46 | 1 |
| pegfilgrastim Drug Profile | 47 | 1 |
| pegfilgrastim Drug Profile | 48 | 1 |
| plinabulin Drug Profile | 49 | 4 |
| Febrile Neutropenia Dormant Projects | 53 | 1 |
| Febrile Neutropenia Product Development Milestones | 54 | 5 |
| Featured News &Press Releases | 54 | 1 |
| Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study | 54 | 1 |
| Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim | 55 | 1 |
| Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study | 55 | 1 |
| Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 | 56 | 1 |
| Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program | 56 | 1 |
| Dec 08, 2015: EMA started the evaluation of Richter s marketing authorisation application for biosimilar pegfilgrastim | 57 | 1 |
| Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA | 57 | 1 |
| Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |